Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceritinib in Relapsed/Refractory ALK+ Hematologic Malignancies
NCT02343679Phase 2Withdrawn
- Start
- May 2015
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ceritinib in hematologic malignancy. Primary endpoint: Overall Response Rate at 5 years. Planned start May 2015; status: withdrawn.
02
Drugs
ceritinib
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT02343679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02343679.